Fenotypizace a kvantifikace T regulačních lymfocytů u pacientů s mnohočetným myelomem pomocí průtokové cytometrie

English version

Authors: Muthu Raja K. R. ^1,2; L. Kovářová ^1,3; J. Štossová ¹; R. Hájek ^1,3,4
Authors‘ workplace: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic ¹; Department of Molecular and Cellular Biology, Faculty of Science, Masaryk University, Brno, Czech Republic ²; Laboratory of Experimental Hematology and Cell Immunotherapy, Department of Clinical Hematology, University Hospital Brno, Czech Republic ³; Department of Internal Medicine – Hematooncology, University Hospital Brno, Czech Republic ⁴
Published in: Klin Onkol 2011; 24(Supplementum 1): 30-33

Overview

Mnohočetný myelom (MM) je onemocnění plazmatických buněk (PC), které bývá často spojeno s poruchami imunity. Fenotypizace a stanovení počtu regulačních T lymfocytů (Tregs) pomocí průtokové cytometrie může být využito k monitorování stavu imunity u myelomových pacientů. Charakterizace funkčního stavu Tregs pomocí proliferačních či inhibičních testů pak může odhalit jejich možnou poruchu. V naší studii bylo zjištěno, že u pacientů s MM jsou počty Tregs zvýšeny oproti zdravým kontrolám, což u těchto pacientů svědčí o deregulaci imunity.

Klíčová slova:
Treg buňky – flow cytometrie – mnohočetný myelom – thalidomid

Tato práce byla podpořena granty MŠMT ČR (MSM0021622434, LC06027), MZd ČR (IGA grants NS10406, NS10408) a GAČR GAP304/10/1395.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do bi omedicínských časopisů.

Sources

1. Kyle RA, Rajkumar SV. Criteria for diagnosis staging risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23(1): 3–9.

2. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010; 149(3): 334–351.

3. Mills KH, Cawley JC. Abnormal monoclonal antibody defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br J Haematol 1983; 53(2): 271–275.

4. Wolf AM, Wolf D, Steurer M et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9(2): 606–612.

5. Fehérvari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 2004; 114(9): 1209–1217.

6. Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24(34): 5373–5380.

7. Beyer M, Kochanek M, Darabi K et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106(6): 2018–2025.

8. Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003; 15(4): 430–435.

9. Vieira PL, Christensen JR, Minaee S et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 2004; 172(10): 5986–5993.

10. Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198(12): 1875–1886.

11. Fischer K, Voelkl S, Heymann J et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4-CD8- double-negative regulatory T cells. Blood 2005; 105(7): 2828–2835.

12. Peng G, Wang HY, Peng W et al. Tumor-infiltrating gamma delta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007; 27(2): 334–348.

13. Wang RF. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum Immunol 2008; 69(11): 811–814.

14. Gil-Guerrero L, Dotor J, Huibregtse IL et al. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta 1. J Immunol 2008; 181(1): 126–135.

15. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 2003; 3(5): 361–370.

16. Cao X. Regulatory T cells and immune tolerance to tumors. Immunol Res 2010; 46(1–3): 79–93.

17. Oderup C, Cederbom L, Makowska A et al. Cytotoxic T lymphocyte antigen-4 dependent down-modulation of costimulatory molecules on dendritic cells in CD4+CD25+ regulatory T-cell-mediated suppression. Immunology 2006; 118(2): 240–249.

18. Beyer M, Kochanek M, Giese T et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006; 107(10): 3940–3949.

19. Feyler S, von Lilienfeld-Toal M, Jarmin S et al. CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4-CD8-αβ TCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009; 144(5): 686–695.

20. Prabhala RH, Neri P, Bae JE et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006; 107(1): 301–304.

21. Gupta R, Ganeshan P, Hakim M et al. Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leuk Res 2010. Epub of print.

22. Brimnes MK, Vangsted AJ, Knudsen LM et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR–/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010; 72(6): 540–547.

23. Atanackovic D, Cao Y, Luetkens T et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 2008; 93(3): 423–430.

24. Wang X, Zheng J, Liu J et al. Increased population of CD4 (+) CD25 (high) regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 2005; 75(6): 468–476.

25. Yang ZZ, Novak AJ, Stenson MJ et al. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T-cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107(9): 3639–3646.

26. Giannopoulos K, Schmitt M, Własiuk P et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008; 22(1): 222–224.

27. Quach H, Ritchie D, Stewart AK et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24(1): 22–32.